Horizon Funds - Horizon Flexible Income ETF
US ˙ BATS ˙ US33938J1060

Introduction

This page provides a comprehensive analysis of the known insider trading history of David Arkowitz. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate David Arkowitz has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:KANT / Kineta, Inc. Director 0
US:IBIO / iBio, Inc. Director 18,382
US:MCRB / Seres Therapeutics, Inc. Chief Financial Officer 182,442
US:FSTX / F-star Therapeutics Inc Director 0
US:FLXN / Horizon Funds - Horizon Flexible Income ETF Chief Financial Officer 220,719
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by David Arkowitz. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases FLXN / Horizon Funds - Horizon Flexible Income ETF - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in FLXN / Horizon Funds - Horizon Flexible Income ETF. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2019-05-31 FLXN Arkowitz David 2,500 11.0507 2,500 11.0507 27,627 223 21.1300 25,199 91.21
2019-05-13 FLXN Arkowitz David 4,000 11.9900 4,000 11.9900 47,960
2018-11-09 FLXN Arkowitz David 4,000 16.5554 4,000 16.5554 66,222
2018-08-09 FLXN Arkowitz David 4,000 23.4200 4,000 23.4200 93,680

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

FLXN / Horizon Funds - Horizon Flexible Income ETF Insider Trades
Insider Sales FLXN / Horizon Funds - Horizon Flexible Income ETF - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in FLXN / Horizon Funds - Horizon Flexible Income ETF. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2021-05-10 FLXN Arkowitz David 2,229 7.2300 2,229 7.2300 16,116 101 4.4 -6,307 -39.14
2021-01-05 FLXN Arkowitz David 6,073 11.1300 6,073 11.1300 67,592
2020-01-03 FLXN Arkowitz David 3,095 3,095

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

FLXN / Horizon Funds - Horizon Flexible Income ETF Insider Trades
Insider Purchases MCRB / Seres Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in FLXN / Horizon Funds - Horizon Flexible Income ETF. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MCRB / Seres Therapeutics, Inc. Insider Trades
Insider Sales MCRB / Seres Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in FLXN / Horizon Funds - Horizon Flexible Income ETF. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MCRB / Seres Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by David Arkowitz as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-07-02 2025-06-30 4 KANT KINETA, INC./DE
Common Stock
D - Sale to Issuer -16,571 0 -100.00
2025-06-25 2025-06-25 4 KANT KINETA, INC./DE
Common Stock
A - Award 6,000 18,141 49.42
2025-06-25 2025-06-23 4 KANT KINETA, INC./DE
Common Stock
F - Taxes -4,706 12,141 -27.93 0.26 -1,224 3,157
2025-06-25 2025-06-23 4 KANT KINETA, INC./DE
Common Stock
M - Exercise 12,500 16,847 287.55 0.61 7,638 10,294
2025-01-13 2025-01-10 4 IBIO iBio, Inc.
Common Stock
P - Purchase 18,382 18,382 2.72 49,999 49,999
2024-02-16 2024-02-16 4 MCRB Seres Therapeutics, Inc.
Common Stock
S - Sale X -3,939 182,442 -2.11 1.08 -4,254 197,037
2024-02-16 2024-02-15 4 MCRB Seres Therapeutics, Inc.
Common Stock
M - Exercise 10,625 186,381 6.05
2023-10-31 2023-10-30 4 MCRB Seres Therapeutics, Inc.
Common Stock
S - Sale X -4,066 175,756 -2.26 1.35 -5,489 237,271
2023-10-31 2023-10-27 4 MCRB Seres Therapeutics, Inc.
Common Stock
M - Exercise 13,209 179,822 7.93
2023-05-01 2023-04-27 4 MCRB Seres Therapeutics, Inc.
Common stock
A - Award 42,500 166,613 34.24
2023-03-09 2023-03-08 4 FSTX F-star Therapeutics, Inc.
Common Stock
U - Other -8,386 0 -100.00 7.12 -59,708
2022-10-31 2022-10-27 4 MCRB Seres Therapeutics, Inc.
Common stock
A - Award 42,500 112,992 60.29
2022-10-31 2022-06-15 4 MCRB Seres Therapeutics, Inc.
Common stock
M - Exercise 5,000 70,492 7.63
2022-07-06 2022-07-05 4 MCRB Seres Therapeutics, Inc.
COMMON STOCK
A - Award 63,492 65,492 3,174.60 3.15 200,000 206,300
2022-02-08 2022-02-04 4 MCRB Seres Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 190,000 190,000
2021-06-07 2021-06-04 4 FSTX F-star Therapeutics, Inc.
Stock Option
A - Award 20,000 20,000
2021-06-04 2021-06-02 4 YMTX YUMANITY THERAPEUTICS, INC.
Stock Option (Right to Buy)
A - Award 14,800 14,800
2021-06-01 3 MCRB Seres Therapeutics, Inc.
Common Stock
2,000
2021-06-01 2021-06-01 4 MCRB Seres Therapeutics, Inc.
Restricted Stock Units
A - Award 5,000 5,000
2021-06-01 2021-06-01 4 MCRB Seres Therapeutics, Inc.
Stock Options (right to buy)
A - Award 270,000 270,000
2021-05-12 2021-05-10 4 FLXN Flexion Therapeutics Inc
Common Stock
S - Sale -2,229 220,719 -1.00 7.23 -16,116 1,595,798
2021-03-03 2021-03-01 4 FLXN Flexion Therapeutics Inc
Stock option (right to buy)
A - Award 20,000 20,000
2021-03-03 2021-03-01 4 FLXN Flexion Therapeutics Inc
Common Stock
A - Award 41,900 222,948 23.14
2021-03-03 2021-03-01 4 FLXN Flexion Therapeutics Inc
Common Stock
A - Award 30,000 181,048 19.86
2021-01-07 2021-01-05 4 FLXN Flexion Therapeutics Inc
Common Stock
S - Sale -6,073 151,048 -3.87 11.13 -67,592 1,681,164
2020-12-28 2020-12-22 4 YMTX YUMANITY THERAPEUTICS, INC.
Common Stock
A - Award 4,347 4,347 23.00 99,981 99,981
2020-11-23 2020-11-19 4 SBPH F-star Therapeutics, Inc.
Warrants
J - Other -1,096 0 -100.00
2020-07-20 2020-07-16 4 FLXN Flexion Therapeutics Inc
Common Stock
A - Award 38,750 157,121 32.74
2020-07-01 2020-06-29 4 PTI PROTEOSTASIS THERAPEUTICS, INC.
Stock Option (Right to Buy)
A - Award 17,400 17,400
2020-06-25 2020-06-24 4 SBPH Spring Bank Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 7,500 7,500
2020-06-24 2020-06-22 4 FLXN Flexion Therapeutics Inc
Common Stock
A - Award 1,303 118,371 1.11 10.83 14,111 1,281,958
2020-05-11 2020-05-07 4 FLXN Flexion Therapeutics Inc
Common Stock
S - Sale X -2,413 117,068 -2.02 10.88 -26,253 1,273,700
2020-03-03 2020-03-02 4 FLXN Flexion Therapeutics Inc
Stock option (right to buy)
A - Award 15,500 15,500
2020-03-03 2020-03-02 4 FLXN Flexion Therapeutics Inc
Common Stock
A - Award 31,000 119,481 35.04
2020-01-07 2020-01-03 4 FLXN Flexion Therapeutics Inc
Common Stock
S - Sale -3,095 88,481 -3.38
2020-01-02 2019-12-31 4 SBPH Spring Bank Pharmaceuticals, Inc.
Common Stock
A - Award 9,098 37,929 31.56
2019-10-01 2019-09-30 4 SBPH Spring Bank Pharmaceuticals, Inc.
Common Stock
A - Award 4,179 28,831 16.95
2019-07-11 2019-07-10 4 SBPH Spring Bank Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 7,500 7,500
2019-07-01 2019-06-28 4 SBPH Spring Bank Pharmaceuticals, Inc.
Common Stock
A - Award 3,896 24,652 18.77
2019-06-24 2019-06-21 4 FLXN Flexion Therapeutics Inc
Common Stock
A - Award 2,152 91,576 2.41 9.81 21,111 898,361
2019-06-03 2019-05-31 4 FLXN Flexion Therapeutics Inc
Common Stock
P - Purchase 2,500 89,424 2.88 11.05 27,627 988,198
2019-05-15 2019-05-13 4 FLXN Flexion Therapeutics Inc
Common Stock
P - Purchase 4,000 86,924 4.82 11.99 47,960 1,042,219
2019-05-09 2019-05-08 4 FLXN Flexion Therapeutics Inc
Common Stock
S - Sale X -2,248 82,924 -2.64 10.06 -22,615 834,215
2019-04-02 2019-03-29 4 SBPH Spring Bank Pharmaceuticals, Inc.
Common Stock
A - Award 1,370 20,756 7.07
2019-03-08 2019-03-06 4 PTI PROTEOSTASIS THERAPEUTICS, INC.
Stock Option (Right to Buy)
A - Award 30,600 30,600
2019-03-05 2019-03-01 4 FLXN Flexion Therapeutics Inc
Stock option (right to buy)
A - Award 18,000 18,000
2019-03-05 2019-03-01 4 FLXN Flexion Therapeutics Inc
Common Stock
A - Award 36,000 85,172 73.21
2019-01-04 2018-12-20 4 FLXN Flexion Therapeutics Inc
Common Stock
J - Other 922 49,172 1.91 10.48 9,663 515,323
2018-11-13 2018-11-09 4 FLXN Flexion Therapeutics Inc
Common Stock
P - Purchase 4,000 48,250 9.04 16.56 66,222 798,798
2018-08-10 2018-08-09 4 FLXN Flexion Therapeutics Inc
Common Stock
P - Purchase 4,000 44,250 9.94 23.42 93,680 1,036,335
2018-06-19 2018-06-18 4 SBPH Spring Bank Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 5,500 5,500
2018-06-04 2018-06-01 4 FLXN Flexion Therapeutics Inc
Stock option (right to buy)
A - Award 115,000 115,000
2018-06-04 2018-06-01 4 FLXN Flexion Therapeutics Inc
Common Stock
A - Award 30,000 40,250 292.68
2018-05-07 3 FLXN Flexion Therapeutics Inc
Common Stock
20,500
2018-05-07 3 FLXN Flexion Therapeutics Inc
Common Stock
20,500
2018-05-07 3 FLXN Flexion Therapeutics Inc
Common Stock
20,500
2017-08-07 2017-08-04 4 SBPH Spring Bank Pharmaceuticals, Inc.
Common Stock
P - Purchase 2,300 19,386 13.46 12.24 28,152 237,285
2017-08-07 2017-08-04 4 SBPH Spring Bank Pharmaceuticals, Inc.
Common Stock
P - Purchase 200 17,086 1.18 12.25 2,450 209,304
2017-06-16 2017-06-15 4 SBPH Spring Bank Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 5,500 5,500
2016-11-23 2016-11-23 4 SBPH Spring Bank Pharmaceuticals, Inc.
Warrant (right to buy)
A - Award 4,386 4,386
2016-11-23 2016-11-23 4 SBPH Spring Bank Pharmaceuticals, Inc.
Common Stock
A - Award 4,386 16,886 35.09 9.12 40,000 154,000
2016-07-29 2016-07-28 4 SBPH Spring Bank Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 5,500 5,500
2016-05-05 3 SBPH Spring Bank Pharmaceuticals, Inc.
Common Stock
25,000
2016-05-05 3 SBPH Spring Bank Pharmaceuticals, Inc.
Common Stock
25,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)